Kytopen

Kytopen is a private, pre-revenue platform technology company developing tools to overcome a major hurdle in cell therapy: scalable and efficient gene delivery. Its flagship Flowfect® technology uses a combination of continuous fluid flow and electric fields to deliver genetic payloads like mRNA and CRISPR-Cas9 RNP to cells rapidly and at high efficiency. By providing a translatable process from small-scale discovery to large-scale manufacturing, Kytopen aims to reduce the time, cost, and risk associated with bringing new cell therapies to market, positioning itself as a critical enabler for the broader cell and gene therapy industry.

Flowfect® technology: a non-viral gene delivery platform combining continuous fluid flow with electric fields for high-efficiency delivery of payloads (mRNA, DNA, CRISPR-Cas9 RNP) to cells. It enables tunable, scalable transfection from small-volume discovery to large-scale manufacturing.

Kytopen competes in the non-viral cell engineering space against other specialized startups and large life science tool providers like MaxCyte (electroporation) and Lonza. Its differentiation lies in the continuous-flow, multi-parameter tuning of its Flowfect process, which aims to offer superior scalability and cell health preservation compared to traditional batch electroporation.